Sentara Norfolk General Hospital

Summary

Sentara Norfolk General Hospital is a medical facility located in Norfolk, Virginia. This center is recognized for care of Heart Failure, Atrial Fibrillation, Cardiovascular Disease, Coronary Artery Disease, Von Willebrand Disease and other specialties. Sentara Norfolk General Hospital is involved with conducting 215 clinical trials across 279 conditions. There are 25 research doctors associated with this hospital, such as Paul Mahoney, MD, David Dexter, MD, Jean Panneton, MD, and Joseph Newton, MD.

Top PIs

Clinical Trials running at Sentara Norfolk General Hospital

Heart Failure

Atrial Fibrillation

Pancreatic Cancer

Bladder Cancer

Colorectal Cancer

Prostate Cancer

Lung Cancer

Mitral Regurgitation

Abdominal Aortic Aneurysm

Ovarian Cancer

Carillon Device

for Heart Failure with Mitral Regurgitation

This trial is testing a device called the Carillon Mitral Contour System, which helps the mitral valve in the heart work better. It targets patients with heart failure and a specific valve problem. The device reshapes the valve to improve its function and reduce symptoms.

Recruiting

1 award

N/A

2 criteria

BI 690517 + Empagliflozin

for Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Recruiting

1 award

Phase 3

2 criteria

Omecamtiv Mecarbil

for Heart Failure

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Recruiting

1 award

Phase 3

10 criteria